The animal models for myasthenia gravis （MG） have become a research hotspot in recent years. While various experimental models partially capture the heterogeneity of MG， due to their respective limitations， it is difficult to achieve a comprehensive emulation of all facets of MG. The experimental autoimmune myasthenia gravis （EAMG） model covers the key cellular mechanisms involved in the immune response against acetylcholine receptor， which provides a basis for understanding the immunological characteristics of MG. The passive transfer model is characterized by simple disease induction， rapidly manifesting the symptom of weakness within 24 hours after a single antibody injection. Genetic engineering models offer more specificity and can accurately simulate the genetic basis of MG， thereby making up for the shortcomings of the EAMG model. Drug-induced models attract researchers with their rapid modeling and do not involve complex immune activation and antigen induction， but with certain limitations in simulating disease complexity. By matching the phenotypes and functional responses of patient serum， the in vitro model allows a more intuitive observation of the role of heterologous cells in disease development， which is closer to clinical reality. This article summarizes the advantages and disadvantages of various experimental models and helps researchers to select the models suitable for different research purposes. This review provides directions for a deeper understanding of the complex mechanisms of this disease， as well as a scientific basis for the development of new therapeutic strategies.